Kymera Therapeutics, Inc.
Regulated industrySells to businessesDevelopment stageTags from an AI model reading the company description.
Key Metrics
- Previous Close
- $121.52
- 52-Week Range
- $63.69 – $142.92
- Market Cap
- $10.34B
- P/E (TTM)
- —
- EPS (TTM)
- -3.64
- Dividend Yield
- 0.00%
Advanced Metrics
- Price/Book
- 6.40
- PEG Ratio
- —
- Return on Equity
- -27.29%
- Return on Assets
- -17.64%
- Gross Margin
- 0.00%
- Operating Margin
- -396.04%
- Profit Margin
- 0.00%
- Current Ratio
- 11.13
- Debt/Equity
- 0.05
- Total Debt
- $76.60M
- Free Cash Flow
- $-164.68M
- Revenue Growth
- —
- Earnings Growth
- —
- Enterprise Value
- $9.45B
Market Snapshot
About
Kymera Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing protein degradation therapies. The company's proprietary Pegasus platform enables the discovery of small molecule protein degraders that target disease-causing proteins for destruction. Kymera's pipeline includes investigational treatments for immunological diseases, oncology, and other therapeutic areas, utilizing targeted protein degradation as a novel mechanism of action.